Humacyte (HUMA) Gross Margin (2025 - 2026)
Humacyte's (HUMA) quarterly Gross Margin came in at 203.2% in Q2 2026, down 23244.0% year-over-year from N/an in Q2 2025, and up 34.81% quarter-over-quarter from 311.72% in Q1 2026.
Powered by 
Analysis
Humacyte (HUMA) Gross Margin (2025 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Gross Margin for 2 consecutive years, with 203.2% the latest figure, recorded in Q2 2026.
- On a quarterly basis, Gross Margin fell 23244.0% year-over-year to 203.2% in Q2 2026; TTM through Jun 2026 was 494.58%, a 55057.0% decrease from a year earlier, with the FY2025 full-year figure at 376.05%, changed N/A from the prior year.
- Gross Margin was 203.2% for Q2 2026 at Humacyte, up from 311.72% in the prior quarter.
- Over five years, Gross Margin peaked at 71.57% in Q1 2025 and troughed at 1844.75% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn | 94.60% |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.34 Bn | 55.72 Mn | 56.10% |
| 4 | Legend Biotech | 3.53 Bn | 2.57 Bn | 251.50 Mn | 64.90% |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn | 94.01% |
| 6 | Beam Therapeutics | 2.53 Bn | 2.53 Bn | - | - |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 94.90% |
| 8 | Sarepta Therapeutics | 2.15 Bn | 1.35 Bn | 251.87 Mn | 62.77% |
| 9 | Vericel | 1.93 Bn | 1.76 Bn | 56.40 Mn | 72.82% |
| 10 | Humacyte | 133.72 Mn | 133.72 Mn | -825,000.00 | -203.20% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -203.20% |
| Mar 31, 2026 | -311.72% |
| Dec 31, 2025 | -1,844.75% |
| Sep 30, 2025 | 65.47% |
| Jun 30, 2025 | 29.24% |
| Mar 31, 2025 | 71.57% |